# SK Life Science, Inc. clinical trials: 43 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 43 trials with SK Life Science, Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by SK Life Science, Inc.: 43 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sk-life-science-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 43
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 10, 2026 | NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | SK Life Science, Inc. | Phase 1 | Recruiting | Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812805) |
| June 11, 2024 | NCT06453213 | Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy | SK Life Science, Inc. | Phase 4 | Active not recruiting | Focal Onset Seizure | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06453213) |
| October 7, 2022 | NCT05572255 | A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally | SK Life Science, Inc. | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05572255) |
| May 24, 2022 | NCT05388435 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | SK Life Science, Inc. | Phase 1/2 | Terminated | Advanced Solid Tumor | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05388435) |
| February 2, 2022 | NCT05219617 | Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | SK Life Science, Inc. | Phase 3 | Recruiting | Seizures, Lennox Gastaut Syndrome | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05219617) |
| October 5, 2021 | NCT05067634 | Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures | SK Life Science, Inc. | Phase 3 | Completed | Partial Epilepsy | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05067634) |
| May 26, 2021 | NCT04903314 | Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures | SK Life Science, Inc. | Phase 1 | Completed | Partial Epilepsy | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04903314) |
| March 10, 2021 | NCT04791553 | Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment | SK Life Science, Inc. | Phase 1 | Completed | Hepatic Impairment | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04791553) |
| December 31, 2020 | NCT04690751 | Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet | SK Life Science, Inc. | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04690751) |
| September 21, 2020 | NCT04557085 | Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS | SK Life Science, Inc. | Phase 3 | Completed | Partial Seizure, Focal Seizure | 519 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04557085) |
| August 20, 2020 | NCT04520360 | Bioavailability and Food Effect Study of 3 Types of Carisbamate | SK Life Science, Inc. | Phase 1 | Completed | Healthy Subjects | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04520360) |
| August 14, 2020 | NCT04513860 | Cenobamate Expanded Access Program (EAP) | SK Life Science, Inc. | Not applicable | Approved for marketing | Partial Epilepsy | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04513860) |
| August 10, 2020 | NCT04505397 | Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects | SK Life Science, Inc. | Phase 1 | Completed | Healthy | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04505397) |
| August 20, 2019 | NCT04062981 | Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome | SK Life Science, Inc. | Phase 1 | Completed | Lennox Gastaut Syndrome | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04062981) |
| May 23, 2019 | NCT03961568 | Cenobamate Open-Label Extension Study for YKP3089C025 | SK Life Science, Inc. | Phase 3 | Completed | Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03961568) |
| November 6, 2018 | NCT03731715 | Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome | SK Life Science, Inc. | Phase 1 | Completed | Lennox Gastaut Syndrome | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03731715) |
| September 20, 2018 | NCT03678753 | Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures | SK Life Science, Inc. | Phase 3 | Completed | Primary Generalized Epilepsy | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03678753) |
| April 26, 2018 | NCT03509285 | A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users | SK Life Science, Inc. | Phase 1 | Completed | Healthy Volunteer | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03509285) |
| July 31, 2017 | NCT03234699 | Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions | SK Life Science, Inc. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03234699) |
| August 28, 2015 | NCT02535091 | Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures | SK Life Science, Inc. | Phase 3 | Completed | Partial Epilepsy | 1,345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02535091) |
| July 31, 2014 | NCT02205099 | A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia | SK Life Science, Inc. | Phase 1/2 | Completed | Schizophrenia | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02205099) |
| November 20, 2013 | NCT01989234 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily... | SK Life Science, Inc. | Phase 2 | Completed | Chronic Idiopathic Constipation | 334 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01989234) |
| May 31, 2013 | NCT01866111 | A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures | SK Life Science, Inc. | Phase 2 | Completed | Partial Epilepsy | 437 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01866111) |
| February 1, 2012 | NCT01523184 | A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation | SK Life Science, Inc. | Phase 2 | Completed | Chronic Constipation, Functional Constipation | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01523184) |
| January 30, 2012 | NCT01521598 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy | SK Life Science, Inc. | Phase 2 | Completed | Painful Diabetic Neuropathy | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01521598) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 2 |
| Phase 2 | 14 |
| Phase 3 | 14 |
| Phase 4 | 1 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 36 |
| Terminated | 3 |
| Recruiting | 2 |
| Active not recruiting | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Seizures | 15 |
| Epilepsies, Partial | 13 |
| Epilepsy | 7 |
| Epilepsy, Complex Partial | 5 |
| Lennox Gastaut Syndrome | 4 |
| Diabetic Neuropathies | 3 |
| Epilepsy, Partial, Motor | 2 |
| Epilepsy, Idiopathic Generalized | 2 |
| Schizophrenia | 1 |
| Essential Tremor | 1 |
| Movement Disorders | 1 |
| Tremor | 1 |
| Neuralgia, Postherpetic | 1 |
| Neuralgia | 1 |
| Herpes Zoster | 1 |
| Blister | 1 |
| Exanthema | 1 |
| Chickenpox | 1 |
| Diabetes Mellitus | 1 |
| Glioblastoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Drug Resistant Epilepsy | 1 |
| Migraine Disorders | 1 |
| Headache | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Damage restoration companies in the United States](https://specstream.ai/data/businesses/damage-restoration-companies/united-states)
- [Radiology practices in the United States](https://specstream.ai/data/businesses/radiology-practices/united-states)
- [Dim sum restaurants in the United States](https://specstream.ai/data/businesses/dim-sum-restaurants/united-states)
- [Resorts in the United States](https://specstream.ai/data/businesses/resorts/united-states)
- [Driving schools in the United States](https://specstream.ai/data/businesses/driving-schools/united-states)
- [Salvadoran restaurants in the United States](https://specstream.ai/data/businesses/salvadoran-restaurants/united-states)
